Key facts
- Notable investors include Endurance28, IT-Farm.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Taudia
- ·The full record, as it builds
Funding rounds
No funding rounds for Taudia are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Taudia
Developer of blood-based protein biomarker technology designed for neurodegenerative diseases. The company's technology automated, sample-to-answer system delivers precise, hands-free protein biomarker quantitation in blood or other complex matrices, enabling healthcare professionals to accelerate drug development for Parkinson's disease and other neurological disorders.
- Sector
- Healthcare
- HQ
- San Carlos, CA, United States
- Founded
- 2024
- Employees
- 9
- Website
- taudia.com/
- Ownership
- Privately Held (backing)
Taudia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Taudia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Taudia in its N-PORT filings yet. We sweep new filings monthly.